Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis

INTRODUCTION: The number of treatment options for metastatic castration‐resistant prostate cancer has increased in recent years. Abiraterone, which selectively inhibits CYP17 in the androgen synthesis pathway, is widely used. Liver metastasis is one of the worst prognostic factors in metastatic cast...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsui, Masahiro, Ohigashi, Takashi, Kosaka, Takeo, Bessho, Hideharu, Arakawa, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292117/
https://www.ncbi.nlm.nih.gov/pubmed/32743362
http://dx.doi.org/10.1002/iju5.12026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292117/
https://www.ncbi.nlm.nih.gov/pubmed/32743362
http://dx.doi.org/10.1002/iju5.12026

Ejemplares similares